AQR Capital Management
GYRE icon

AQR Capital Management’s Gyre Therapeutics GYRE Stock Holding History

AQR Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,188
Closed -$121K – 2254
2021
Q1 		$121K Hold
3,188
– – ﹤0.01% 2148
2020
Q4 		$151K Sell
3,188
-71
-2% -$3.07K ﹤0.01% 2122
2020
Q3 		$105K Buy
+3,259
New +$128K ﹤0.01% 2129
2019
Q2 		– Sell
-11,334
Closed -$689K – 2120
2019
Q1 		$689K Sell
11,334
-3,467
-23% -$223K ﹤0.01% 1689
2018
Q4 		$876K Buy
14,801
+2,298
+18% +$169K ﹤0.01% 1563
2018
Q3 		$1.01M Buy
12,503
+9,403
+303% +$745K ﹤0.01% 1703
2018
Q2 		$271K Buy
+3,100
New +$544K ﹤0.01% 2151

Other funds holding GYRE

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

AQR Capital Management's GYRE Position: Q2 2021 in Review

AQR Capital Management sold out of Gyre Therapeutics (GYRE) in Q2 2021, closing a stake of 3,188 shares — an estimated $121K sold.

AQR Capital Management first reported a position in GYRE in Q2 2018 and held it in 7 quarters. The position peaked at $1.01M in Q3 2018. 69 funds tracked by Wall St. Rank hold GYRE as of Q2 2021.

  • AQR Capital Management reported no remaining Gyre Therapeutics position as of Q2 2021 after selling out during the quarter.
  • AQR Capital Management sold 3,188 Gyre Therapeutics shares in Q2 2021, an estimated $121K.
  • AQR Capital Management first reported a position in Gyre Therapeutics in Q2 2018 and held it in 7 quarters.
  • AQR Capital Management's Gyre Therapeutics position peaked at $1.01M in Q3 2018.
  • 69 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2021.

Based on AQR Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.